Validation of EuroSCORE II, ACEF Score, CHA(2)DS(2)-VASc, and CHA(2)DS(2)-VA in Patients Undergoing Left Main Coronary Artery Angioplasty: Analysis from All-Comers BIA-LM Registry

左主干冠状动脉血管成形术患者中 EuroSCORE II、ACEF 评分、CHA₂DS₂-VASc 和 CHA₂DS₂-VA 的验证:来自 BIA-LM 注册研究的全入组患者分析

阅读:1

Abstract

Background: Simple surgical and clinical risk scores are useful in mortality prediction. Aims: The study's aim was to validate three scores in real-world registry of percutaneous coronary intervention (PCI) for the left main coronary artery (LMCA). Methods: All data were obtained from the BIA-LM Registry. Discrimination and calibration of EuroSCORE II, ACEF, CHA(2)DS(2)-VASc, and CHA(2)DS(2)-VA were assessed with receiver operating characteristic (ROC) curves analysis and Hosmer-Lemeshow (HL) test. Results: The final cohort included 851 patients, median age was 71, and 156 patients had history of previous coronary artery bypass grafting (CABG). Median EuroSCORE II, ACEF, CHA(2)DS(2)-VASc, and CHA(2)DS(2)-VA were 3.1% (IQR 5.4%), 1.56 (IQR 0.9), 4 (IQR 2), and 4 (IQR 2), respectively. In the short- (30 days) and long-term (mean 4.1 years), there were 27 and 318 deaths. In short-term, EuroSCORE II showed the best discrimination in the overall population and subgroup with unprotected LMCA [area under the curve (AUC) 0.804, 95% CI 0.717-0.890 and AUC 0.826, 95% CI 0.737-0.913, respectively, p < 0.001 for comparisons with other models), with the best cut-off value at 7.1%. In long-term observation, EuroSCORE II and ACEF showed good predictive value (overall population: AUC 0.716, 95% CI 0.680-0.750 and AUC 0.725, 95% CI 0.690-760, respectively). In short- and long-term observation, EuroSCORE II and ACEF showed poor calibration (HL test p < 0.05) as compared to CHA(2)DS(2)-VASc (HL test p = 0.40 and 0.18). Conclusions: EuroSCORE II showed good mortality prediction in short-term observation; however, its predicted risk should be interpreted with caution due to poor calibration. ACEF and EuroSCORE II may be useful in long-term mortality prediction.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。